{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:49:39Z","timestamp":1792003779946,"version":"4.4.0"},"reference-count":35,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Potassium\u2010competitive acid blockers (P\u2010CABs) are emerging as novel treatments for acid\u2010related disorders including gastroesophageal reflux disease. Tegoprazan and revaprazan are approved P\u2010CABs in South Korea, but the pharmacodynamics and safety\/tolerability of the two drugs have never been compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To evaluate the pharmacodynamics and safety\/tolerability of tegoprazan and revaprazan after single and multiple oral doses<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A randomised, open\u2010label, active\u2010controlled study was conducted in <jats:italic>Helicobacter pylori<\/jats:italic>\u2010negative healthy Korean male subjects. Tegoprazan 50\u00a0mg or revaprazan 200\u00a0mg was administered orally, once daily for 7\u00a0days; 24\u2010h intragastric pH monitoring and serum gastrin were measured for pharmacodynamic evaluation. Safety parameters including serum microRNA\u2010122 (miR\u2010122) level were also collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After a single dose, the %Time pH \u22654 for tegoprazan was greater than that for revaprazan (54.5% vs 25.1%). After multiple doses, the %Time pH \u22654 for tegoprazan was also greater than that for revaprazan (68.2% vs 25.3%). %Time pH \u22654 during 12\u00a0hours at nighttime for tegoprazan was greater than that for revaprazan (71.8% vs 31.9%). The changes in the serum gastrin were not clinically significant for either drug. Despite the slight increases of serum miR\u2010122 for each drug, tegoprazan and revaprazan were well tolerated considering other safety parameters including AST and ALT levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Tegoprazan 50\u00a0mg showed stronger gastric acid suppression than revaorazan 200\u00a0mg. Both drugs were well tolerated.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.16121","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:37:57Z","timestamp":1693809477000},"page":"1640-1647","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects"],"prefix":"10.1111","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-0323","authenticated-orcid":false,"given":"Jung","family":"Sunwoo","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2858-1057","authenticated-orcid":false,"given":"Sang Chun","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6275-8587","authenticated-orcid":false,"given":"Jaeseong","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7140-3032","authenticated-orcid":false,"given":"Mu Seong","family":"Ban","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yeon","family":"Nam","sequence":"additional","affiliation":[{"name":"Division of Clinical Development HK inno.N Corp. Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongtae","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Clinical Development HK inno.N Corp. Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geun Seog","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Clinical Development HK inno.N Corp. Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-7225","authenticated-orcid":false,"given":"Kyung\u2010Sang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8384-3139","authenticated-orcid":false,"given":"In\u2010Jin","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1713-9194","authenticated-orcid":false,"given":"SeungHwan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002280"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.70.Suppl_5.S4"},{"key":"e_1_2_8_4_1","first-page":"11","article-title":"Nocturnal acid breakthrough\u2013approach to management","volume":"6","author":"Tutuian R","year":"2004","journal-title":"MedGenMed"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-2-132"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.20.153"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm18029"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.10.022"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm18001"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.04.047"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e32832c1504"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13121"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4866-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.4292\/wjgpt.v9.i7.63"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15185"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15438"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06408.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000200917"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm.2013.19.1.25"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01893.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14818"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000484688"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.17.s1.3.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.146415"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003261321"},{"key":"e_1_2_8_27_1","first-page":"312","article-title":"Phase III clinical trial of revaprazan (Revanex $^{(R)} $) for gastric ulcer","volume":"34","author":"Chang R","year":"2007","journal-title":"Clin Endosc"},{"key":"e_1_2_8_28_1","unstructured":"Institute KHID.Pharmaceutical industry analysis report.2017."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.03976.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12095"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.25.379"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-4014-0"},{"key":"e_1_2_8_33_1","first-page":"1428","article-title":"Circulating microRNA\u2010122 as a potential biomarker for liver injury","volume":"5","author":"Ding X","year":"2012","journal-title":"Mol Med Rep"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.12.107"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1571"},{"key":"e_1_2_8_36_1","unstructured":"Yuhan Corporation.Prescribing information. REVANEX\u00ae (in Korean).2012.https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetail?itemSeq=200703117. [cited 06 May 2020]."}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.16121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:38:18Z","timestamp":1693809498000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.16121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":35,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/apt.16121"],"URL":"https:\/\/doi.org\/10.1111\/apt.16121","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"2020-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}